Literature DB >> 10997620

The GH/IGF-I axis in obesity: influence of neuro-endocrine and metabolic factors.

M Maccario1, S Grottoli, M Procopio, S E Oleandri, R Rossetto, C Gauna, E Arvat, E Ghigo.   

Abstract

In this review we propose an integrated neuro-endocrine-metabolic point of view on the alterations (adaptations?) of GH/IGF-1 axis in obesity, summarizing the evidence from the literature, particularly focusing the data on humans and adding where possible results from our studies in this field. It is well-known that GH secretion is deeply impaired in overweight patients: we reviewed the multiple mechanisms underlying this issue, considering either central (CNS-related, such as impairment of GHRH tone or increased somatostatin release) or peripheral (ie metabolic: insulin, free fatty acids, glucose) factors. A central point of the debate about GH insufficiency in obesity is if it represents a simple adaptive phenomenon or reflects a true impairment of the axis activity. Evaluation of IGF-I levels and generation in obesity was the mean used to address this question: a bulk of evidence on IGF-I balance in human obesity has been provided, but the matter is still uncertain and unsolved.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997620     DOI: 10.1038/sj.ijo.0801289

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  24 in total

Review 1.  Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.

Authors:  E Ghigo; G Aimaretti; E Arvat; F Camanni
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

Review 2.  Does the pituitary somatotrope play a primary role in regulating GH output in metabolic extremes?

Authors:  Raul M Luque; Manuel D Gahete; Jose Cordoba-Chacon; Gwen V Childs; Rhonda D Kineman
Journal:  Ann N Y Acad Sci       Date:  2011-03       Impact factor: 5.691

3.  GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.

Authors:  F Orio; S Palomba; A Colao; T Russo; C Dentico; L Tauchmanovà; S Savastano; C Nappi; C Sultan; F Zullo; G Lombardi
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

4.  Glucagon administration elicits blunted GH but exaggerated ACTH response in obesity.

Authors:  F Tassone; S Grottoli; R Rossetto; B Maccagno; C Gauna; R Giordano; E Ghigo; M Maccario
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

5.  Insulin and IGF-I inhibit GH synthesis and release in vitro and in vivo by separate mechanisms.

Authors:  Manuel D Gahete; José Córdoba-Chacón; Qing Lin; Jens C Brüning; C Ronald Kahn; Justo P Castaño; Helen Christian; Raúl M Luque; Rhonda D Kineman
Journal:  Endocrinology       Date:  2013-05-13       Impact factor: 4.736

6.  Dose-dependent relationship between severity of pediatric obesity and blunting of the growth hormone response to exercise.

Authors:  Stacy R Oliver; Jaime S Rosa; Timothy D C Minh; Andria M Pontello; Rebecca L Flores; Marcia Barnett; Pietro R Galassetti
Journal:  J Appl Physiol (1985)       Date:  2009-10-29

7.  Plasma levels of acylated ghrelin during an oral glucose tolerance test in obese children.

Authors:  E Lányi; K Csernus; E Erhardt; K Tóth; B Urbán; L Lénárd; D Molnár
Journal:  J Endocrinol Invest       Date:  2007-02       Impact factor: 4.256

8.  Acute ghrelin response to intravenous dexamethasone administration in idiopathic short stature or isolated idiopathic growth hormone-deficient children.

Authors:  G Radetti; F Prodam; S Lauriola; G Di Dio; G D'Addato; G Corneli; S Bellone; G Bona
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

Review 9.  Obesity, growth hormone and exercise.

Authors:  Gwendolyn A Thomas; William J Kraemer; Brett A Comstock; Courtenay Dunn-Lewis; Carl M Maresh; Jeff S Volek
Journal:  Sports Med       Date:  2013-09       Impact factor: 11.136

10.  Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency.

Authors:  C Di Somma; R Pivonello; G Pizza; A De Rosa; G Lombardi; A Colao; S Savastano
Journal:  J Endocrinol Invest       Date:  2009-09-30       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.